Same Indication

Nivolumab vs Ramipril

Nivolumab vs Ramipril: Overview

This comparison examines the pharmacological differences between Nivolumab and Ramipril.

Mechanism of Action

Nivolumab: Fully human anti-PD-1 IgG4 monoclonal antibody restoring T-cell anti-tumor activity.

Ramipril: Prodrug converted to ramiprilat; ACE inhibitor.

Pharmacokinetics

Half-life: Nivolumab — 27 days; Ramipril — 13-17 hours.

Chemical Properties

Molecular Formula: Ramipril — C23H32N2O5.

Molecular Weight: Ramipril — 416.5120 g/mol.

Type: Nivolumab — Antibody; Ramipril — Small molecule.